ArticleJournal of bone oncology2026
Targeting the Hippo/YAP-TAZ pathway increases X-ray sensitivity in chondrosarcoma spheroids and is associated with autophagic disruption.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chondrosarcomas are malignant cartilage-forming bone tumors with limited therapeutic options, as surgical resection remains the only curative treatment, while chemo- and radiotherapy show limited efficacy due to intrinsic resistance mechanisms. Dysregulation of the Hippo signaling pathway been associated with tumor progression and therapy resistance and has emerged as a promising experimental target across several cancer entities. However, its relevance in chondrosarcoma remains unclear, particularly with regard to potential radiosensitizing effects. Methods: Human chondrosarcoma (SW-1353 and Cal78) and healthy chondrocyte (HC) spheroids were treated with Verteporfin (VP) alone or in combination with X-ray irradiation. Cell viability, Hippo/YAP-TAZ signaling, autophagy-associated markers, DNA damage, apoptosis, ultrastructural alterations, and gene expression were analyzed using ATP assays, immunoblotting, RT-qPCR, immunohistochemistry, and transmission electron microscopy. Results: VP treatment caused a dose-dependent decline in cell proliferation and suppressed key YAP/TAZ target genes, both in chondrosarcoma cells and HC, alongside downregulation of Hippo pathway components and proliferative markers like cMyc and PCNA. Combined with X-ray irradiation, these effects were amplified, supporting a potential radiosensitizing activity of VP in this preclinical model. Ultrastructural and molecular data showed that VP disrupted autophagic balance in all cell types, leading to mitochondrial damage, lipid accumulation, and nuclear fragmentation. Despite the higher basal autophagy in HC cells, VP led to cell death involving autophagy, apoptosis, and DNA damage, evidenced by increased LC3B-II, Beclin, γH2AX, and PARP cleavage. Enhanced DNA damage markers and altered p53-MDM2 signaling after treatment reflect the genotoxic stress induced. Conclusion: Our data suggest that VP, particularly in combination with irradiation, is associated with disruption of multiple survival pathways in chondrosarcoma cells, offering a promising avenue for therapeutic intervention. Future studies should investigate the interplay between autophagy, apoptosis, and Hippo signaling to enable their therapeutic targeting in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.